SU9516 promotes myogenic differentiation of human induced pluripotent stem cells

Macromolecular Research · Springer Nature · 2026-11-19 · DOI: 10.1007/s10616-026-01108-2

Abstract

Human-induced pluripotent stem cells (hiPSCs) have emerged as a promising platform for drug screening and disease modeling, offering a human-relevant alternative to animal models. However, efficient differentiation of hiPSCs into skeletal myotubes remains a significant challenge. In this study, we developed a novel differentiation protocol that incorporate SU9516, a small-molecule compound known to enhance integrin α7 expression, to promote myogenic differentiation of hiPSCs. By optimizing the concentration and timing of administration, we found that 1 µM SU9516 significantly improved differentiation efficiency without inducing cytotoxicity. Through image-based analysis and biological assays, we observed significant enhancements in myotube length, fusion ratio, and differentiation ratio, active tension augmentation accompanied by the upregulated expression of muscle-specific markers, including myosin heavy chain (MHC), M-cadherin, and myogenin. Furthermore, both mRNA and protein analyses confirmed the upregulation of integrin α7 before differentiation, suggesting that increased integrin α7 expression may be associated with the differentiation-promoting effects of SU9516. Our results suggest that CDK2 inhibition alone is unlikely to account for the differentiation-promoting effect of SU9516. This study presents a skeletal muscle differentiation model and lays a foundation for future research on organoid culture systems to better mimic the in vivo environment.

Read at publisher →

Similar articles